Actively Recruiting
Feasibility of Ambulatory Talc. Pleurodesis
Led by David Rollins · Updated on 2024-11-12
15
Participants Needed
1
Research Sites
55 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients with malignant pleural disease often experience a significant symptom burden and a short life expectancy. The cornerstone of their treatment is relieving breathlessness by draining fluid from around the lungs and attempting to prevent further fluid build up. Inpatient chest drainage and talc pleurodesis remains the most successful method of stopping the fluid build up but this often requires an average hospital stay of four days. This can be an inappropriate length of time for this patient group. Our study would investigate whether this treatment could be provided on an outpatient, ambulatory basis and facilitate a greater quality of life. The investigators would assess deliverability of the trial protocol and collect patient feedback to see if our patients consider it an acceptable and worthwhile intervention.
CONDITIONS
Official Title
Feasibility of Ambulatory Talc. Pleurodesis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Malignant pleural effusion
- Life expectancy greater than 30 days
- WHO performance status 1-2, or 3 if due to breathlessness
You will not qualify if you...
- Previous failed pleurodesis on the affected side
- Known non-expansile lung
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
North Tees and Hartlepool NHS foundation trust
Stockton-on-Tees, County Durham, United Kingdom, TS19 8PE
Actively Recruiting
Research Team
K
Kevin Conroy, MBBS, FRCP
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here